BRPI0909310A2 - c2orf18 como gene alvo para terapia e diagnóstico de câncer - Google Patents

c2orf18 como gene alvo para terapia e diagnóstico de câncer

Info

Publication number
BRPI0909310A2
BRPI0909310A2 BRPI0909310A BRPI0909310A BRPI0909310A2 BR PI0909310 A2 BRPI0909310 A2 BR PI0909310A2 BR PI0909310 A BRPI0909310 A BR PI0909310A BR PI0909310 A BRPI0909310 A BR PI0909310A BR PI0909310 A2 BRPI0909310 A2 BR PI0909310A2
Authority
BR
Brazil
Prior art keywords
c2orf18
diagnosis
target gene
cancer therapy
cancer
Prior art date
Application number
BRPI0909310A
Other languages
English (en)
Portuguese (pt)
Inventor
Nakagawa Hidewaki
Nakatsuru Shuichi
Nakamura Yusuke
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0909310A2 publication Critical patent/BRPI0909310A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303Liver or Pancreas
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
BRPI0909310A 2008-03-12 2009-03-10 c2orf18 como gene alvo para terapia e diagnóstico de câncer BRPI0909310A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3603508P 2008-03-12 2008-03-12
PCT/JP2009/001057 WO2009113295A1 (en) 2008-03-12 2009-03-10 C2orf18 as target gene for cancer therapy and diagnosis

Publications (1)

Publication Number Publication Date
BRPI0909310A2 true BRPI0909310A2 (pt) 2017-06-27

Family

ID=41064968

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909310A BRPI0909310A2 (pt) 2008-03-12 2009-03-10 c2orf18 como gene alvo para terapia e diagnóstico de câncer

Country Status (9)

Country Link
US (1) US20110098339A1 (enExample)
EP (1) EP2262541A4 (enExample)
JP (1) JP2011518541A (enExample)
KR (1) KR20100128326A (enExample)
CN (1) CN102026672A (enExample)
BR (1) BRPI0909310A2 (enExample)
CA (1) CA2718382A1 (enExample)
RU (1) RU2010141742A (enExample)
WO (1) WO2009113295A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116794325A (zh) * 2023-06-15 2023-09-22 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101406314B1 (ko) * 2011-07-19 2014-06-12 연세대학교 산학협력단 췌장암 암 줄기세포 특성에 기초한 췌장암의 치료용 타겟

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110593A2 (en) * 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
KR20070101610A (ko) * 2006-04-11 2007-10-17 주식회사 바이오인프라 Ant2 유전자의 발현을 억제하는 작은 간섭 rna를이용한 암 유전자 치료 및 항암제 내성 극복방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116794325A (zh) * 2023-06-15 2023-09-22 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用

Also Published As

Publication number Publication date
JP2011518541A (ja) 2011-06-30
WO2009113295A1 (en) 2009-09-17
CA2718382A1 (en) 2009-09-17
RU2010141742A (ru) 2012-04-20
EP2262541A1 (en) 2010-12-22
CN102026672A (zh) 2011-04-20
KR20100128326A (ko) 2010-12-07
US20110098339A1 (en) 2011-04-28
EP2262541A4 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
BRPI0924549A2 (pt) nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
EP2373794A4 (en) NECTINE-4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS OF CANCER
HUE072183T2 (hu) Génterápia neurodegeneratív betegségekre
BRPI1015215A2 (pt) porções de ligação alvo armadas com amatoxina para o tratamento de câncer
BRPI1014099A2 (pt) alvo bioabsorvível para procedimento de diagnóstico ou terapêutico
BR112012005594A2 (pt) tratamento de câncer
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
IL218118A0 (en) Target genes for cancer therapy
LT3192529T (lt) Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BR112012002797A2 (pt) tratamento de câncer de próstata
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
EP2340851A4 (en) DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
BRPI0922884A2 (pt) compostos para tratamento de câncer
EP2432539A4 (en) Hyperthermia assisted radiation therapy
SG11201503363WA (en) Ly75 as cancer therapeutic and diagnostic target
EP2329044A4 (en) PRMT1 FOR TARGET GENES FOR THE TREATMENT AND DIAGNOSIS OF CANCER
BRPI1011912A2 (pt) l-serina para uso como medicamento para prevenir e/ou tratar uma reação inflamatória da pele.
BRPI0920743A2 (pt) ribonucleases terapeuticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]